2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整

2016-10-01 国外内分泌相关专家小组(统称) J Assoc Physicians India.2016.10.1

糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。

中文标题:

2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整

英文标题:

Consensus Statement on Dose Modifications of Anti Diabetic Agents used in Patients with Diabetes and Chronic Kidney Disease

发布日期:

2016-10-01

简要介绍:

糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。

 

拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整)] GetToolGuiderByIdResponse(projectId=1, id=20bf51c001ae2321, title=2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整, enTitle=Consensus Statement on Dose Modifications of Anti Diabetic Agents used in Patients with Diabetes and Chronic Kidney Disease, guiderFrom=J Assoc Physicians India.2016.10.1, authorId=null, author=, summary=糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。 , cover=, journalId=null, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sat Oct 01 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=<P>糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>糖尿病</FONT>相关指南:</STRONG><BR> <UL> <LI><A title=2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=07fcf1c001a668d7">2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识</A> <LI><A title="2017 ACOG实践简报:妊娠期糖尿病(No.180)" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=6e3741c001a65561">2017 ACOG实践简报:妊娠期糖尿病(No.180)</A> <LI><A title=非酒精性脂肪性肝病的治疗—欧洲肥胖-2型糖尿病-消化临床实践指南解读 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=adce11c001a538ff">非酒精性脂肪性肝病的治疗—欧洲肥胖-2型糖尿病-消化临床实践指南解读</A> <LI><A title="2017 亚洲国家循证治疗建议:糖尿病性黄斑水肿" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=289d41c001a46542">2017 亚洲国家循证治疗建议:糖尿病性黄斑水肿</A> <LI><A title=糖尿病微循环障碍临床用药专家共识 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=094761c001a44164">糖尿病微循环障碍临床用药专家共识</A> 更多信息请点击:<A target=_blank href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85">有关糖尿病更多指南</A></LI></UL>, tagList=[TagDto(tagId=216, tagName=糖尿病), TagDto(tagId=2551, tagName=慢性肾病), TagDto(tagId=9905, tagName=抗糖尿病药物), TagDto(tagId=54916, tagName=剂量调整)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5071, appHits=463, showAppHits=7, pcHits=3385, showPcHits=1587, likes=135, shares=17, comments=5, approvalStatus=1, publishedTime=Fri Jul 21 16:08:25 CST 2017, publishedTimeString=2016-10-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Jul 21 16:08:25 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 12:57:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整)])
2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=340546, encodeId=76953405468d, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ba2215278, createdName=鹏远, createdTime=Fri Aug 24 11:36:20 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230627, encodeId=e12623062e05, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Aug 06 08:25:17 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227561, encodeId=7d5822e561e1, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 29 08:04:35 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225612, encodeId=713222561298, content=一体多病很常见,规范用药才合理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Mon Jul 24 06:25:22 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224896, encodeId=92dc224896a9, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 22 07:02:07 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2018-08-24 鹏远

    学习了,谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=340546, encodeId=76953405468d, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ba2215278, createdName=鹏远, createdTime=Fri Aug 24 11:36:20 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230627, encodeId=e12623062e05, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Aug 06 08:25:17 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227561, encodeId=7d5822e561e1, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 29 08:04:35 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225612, encodeId=713222561298, content=一体多病很常见,规范用药才合理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Mon Jul 24 06:25:22 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224896, encodeId=92dc224896a9, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 22 07:02:07 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-08-06 惠映实验室

    学习了。谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=340546, encodeId=76953405468d, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ba2215278, createdName=鹏远, createdTime=Fri Aug 24 11:36:20 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230627, encodeId=e12623062e05, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Aug 06 08:25:17 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227561, encodeId=7d5822e561e1, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 29 08:04:35 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225612, encodeId=713222561298, content=一体多病很常见,规范用药才合理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Mon Jul 24 06:25:22 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224896, encodeId=92dc224896a9, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 22 07:02:07 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-29 惠映实验室

    学习了,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=340546, encodeId=76953405468d, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ba2215278, createdName=鹏远, createdTime=Fri Aug 24 11:36:20 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230627, encodeId=e12623062e05, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Aug 06 08:25:17 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227561, encodeId=7d5822e561e1, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 29 08:04:35 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225612, encodeId=713222561298, content=一体多病很常见,规范用药才合理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Mon Jul 24 06:25:22 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224896, encodeId=92dc224896a9, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 22 07:02:07 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-24 舒心和人

    一体多病很常见,规范用药才合理

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=340546, encodeId=76953405468d, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1ba2215278, createdName=鹏远, createdTime=Fri Aug 24 11:36:20 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230627, encodeId=e12623062e05, content=学习了。谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Aug 06 08:25:17 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227561, encodeId=7d5822e561e1, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 29 08:04:35 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225612, encodeId=713222561298, content=一体多病很常见,规范用药才合理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160907/IMG57D00CF1965701770.jpg, createdBy=565c1948251, createdName=舒心和人, createdTime=Mon Jul 24 06:25:22 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224896, encodeId=92dc224896a9, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Jul 22 07:02:07 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-22 惠映实验室

    学习了,谢谢

    0